Case 32-2005: A 34-year-old HIV-positive woman who desired to become pregnant

New England Journal of Medicine

Volumn 353, Issue 16, 2005, Pages

  Riley, Laura E ^a,c   Yawetz, Sigal ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; ANTIRETROVIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; OBSTETRICS; PREGNANCY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT PLANNING; UTERINE CERVIX DYSPLASIA; VERRUCA VULGARIS; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DISEASE TRANSMISSION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; METHODOLOGY; NEWBORN; PAPILLOMA VIRUS; PREGNANCY COMPLICATION; PRENATAL CARE; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CESAREAN SECTION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV SEROPOSITIVITY; HUMANS; INFANT, NEWBORN; LAMIVUDINE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS; VIRAL LOAD; ZIDOVUDINE;

EID: 26844475871     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc059023     Document Type: Article

References (29)

1. Minkoff H, Remington JS, Holman S, Ramirez R, Goodwon S, Landesman S. Vertical transmission of toxoplasma by human immunodeficiency virus infected women. Am J Obstet Gyneocol 1997;176:555-9.
2. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-7.
3. Hunt CM, Carson KL, Sharara AI. Hepatitis C in pregnancy. Obstet Gynecol 1997;89:883-90.
4. Massad LS, Riester KA, Anastos KM, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. J Acquir Immune Defic Syndr 1999;21:33-41.
5. Eckert LO, Watts DH, Koutsky LA, et al. A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Infect Dis Obstet Gynecol 1999;7:158-64.
6. Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 1998;178:365-73.
7. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003;101:645-52.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 29, 2004. (Accessed September 23, 2005, at http://aidsinfo.nih.gov.)
9. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
10. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29. [Erratum, Lancet 2002;360:1178.]
11. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. February 24, 2005. (Accessed September 23, 2005, at http://aidsinfo.nih.gov.)
12. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmissionof human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385-93.
13. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
14. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
15. Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
16. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001;183:539-45.
17. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects: Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-F247.
18. The European Collaborative Study and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14:2913-20.
19. Tuomala RE, Shapiro D, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-70.
20. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
21. Stek A, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. Presented at the 15th International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
22. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.
23. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:1035-9. [Erratum, Lancet 1999;353:1714.]
24. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2001;26:236-45.
25. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus occurrence at delivery: a systematic review. Obstet Gynecol 2003;102:1396-403.
26. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9.
27. de Cueto M, Sanchez MJ, Sampedro A, Miranda JA, Herruzo AJ, Rosa-Fraile M. Timing of intrapartum ampicillin and prevention of vertical transmission of group B streptococcus. Obstet Gynecol 1998;91:112-4.
28. American Academy of Pediatrics Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus in the United States. Pediatrics 1995;96:977-99.
29. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1 infected women. Lancet 1998;351:1238-41.